Status:
NOT_YET_RECRUITING
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
INSERM UMR S 1136
iPLesp
Conditions:
HIV Seropositivity
HIV Drug Resistance
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
Detailed Description
This is a national, multicenter, cross-sectional study with both retrospective and prospective data collection : Retrospective phase (2019-2024): Data will be collected from all participants diagnose...
Eligibility Criteria
Inclusion
- Participant (male or female) aged 18 years or older ;
- Participant newly diagnosed in the laboratory, for whom mandatory HIV seropositivity reporting to Santé Publique France (SPF) is required ;
- Participant naïve to all antiretroviral treatments (except PrEP and/or post-exposure prophylaxis \[PEP\]) ;
- Participant with an available HIV resistance genotype, including amplification of at least reverse transcriptase and protease ;
- Participant who has not objected to participating in the study.
Exclusion
- Participant who objects to the use of their data ;
- Participant currently on antiretroviral treatment ;
- Participant subject to legal protection measures (safeguard of justice).
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2036
Estimated Enrollment :
30060 Patients enrolled
Trial Details
Trial ID
NCT07146529
Start Date
September 1 2025
End Date
September 1 2036
Last Update
August 28 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.